10 Biotech Stocks Screaming a Buy

Page 9 of 9

1. Verona Pharma plc (NASDAQ:VRNA)

Year to Date Gain as of June 18: 92.80%

Number of Hedge Fund Holders as of Q1: 51

Verona Pharma plc (NASDAQ:VRNA) is one of the 10 biotech stocks screaming a buy. On June 17, Roth Capital increased its price target to $116 from $92 while reiterating a Buy rating. The adjustment follows remarks by Dr Frank Sciurba, who discussed unmet chronic obstructive pulmonary disease needs.

The doctor shared positive insights on the company’s product Ohtuvayre, highlighting its complementary role in newly approved biologics. According to Roth Capital, the enhanced understanding of Verona Pharma’s Ohtuvayre’s distinctive efficacy and risk profile is already sparking greater interest among investors.

Consequently, the research firm raised its price target in response to the increased attention and appreciation of Verona Pharma’s offering. The research firm remains bullish about the company’s growth potential.

Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases. It focuses on developing treatments for chronic obstructive pulmonary disease (COPD). They are known for their product, ensifentrine, an investigational, inhaled, small molecule that acts as a dual inhibitor of phosphodiesterase 3 and 4 (PDE3 and PDE4), combining bronchodilator and anti-inflammatory properties.

While we acknowledge the potential of Verona Pharma plc (NASDAQ:VRNA) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than VRNA and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

Page 9 of 9